EUVIMEDEUVIMED entdecken
Crossref

Donor Lymphocyte Infusion Is a Feasible Way to Improve Survival in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Who Relapse after Allogeneic Stem Cell Transplantation

Lia Minculescu, Joanne Reekie, Soeren Lykke Petersen, Brian Thomas Kornblit, Ida Schjoedt, Niels Smedegaard Andersen, Lisbeth Pernille Andersen, Anne Fischer-Nielsen, Eva Kannik Haastrup, Lone Smidstrup Friis, Henrik Sengelov

Acta Haematologica · 2024 · 147 (3) · 325-332

DOI: 10.1159/000534315 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Haematologica, online erschienen am 12.10.2023. Verfasst von Lia Minculescu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Lymphocyte Transfusion, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 5-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Donor lymphocyte infusion (DLI) is used to induce remission in patients who relapse after allogeneic stem cell transplantation (allo-HSCT). During the last decade, the hypomethylating agent Azacitidine has been used together with DLI for a synergistic graft-versus-leukemia (GVL) effect. Here, we report results of DLI/Azacitidine treatment from a retrospective single-center study.

Methods

Fifty AML/MDS patients treated for relapse after allo-HSCT between 2001 and 2020 with DLI at the Department of Hematology, at Rigshospitalet, Copenhagen University Hospital were included for analyses. A subgroup of patients who obtained complete remission (CR) after reinduction chemotherapy, received DLI in combination with low-dose (32 mg/m2) Azacitidine.

Results

Overall survival in all patients after DLI treatment was 59% at 2 years and 20% at 5 years. Relapse-free survival in patients in CR prior to DLI was 32% after 2 years and 7% after 5 years. In the DLI + low-dose-Azacitidine group, 5-year relapse-free survival was 40%.

Conclusion

DLI remains an effective treatment in post-transplant relapse leaving one-fifth of patients’ long-term survivors. Our results support the concomitant use of low-dose Azacitidine in the future use of DLI in order to enhance the GVL effect of donor lymphocytes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteMyelodysplastic SyndromesLymphocyte TransfusionHematopoietic Stem Cell TransplantationAzacitidineTransplantation, HomologousHumansMiddle AgedFemaleMaleAdultAgedRetrospective StudiesRecurrenceYoung Adult

Stichwörter der Autor:innen

Acute myeloid leukemiaAllogeneic hematopoietic stem cell transplantationDonor lymphocyte infusionGraft-versus-tumor effectHypomethylating agents

Substanzen

Azacitidine

Autor:innen und Institutionen

  • Department of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
  • Department of Infectious Diseases, PERSIMUNE, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
  • Department of Hematology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
  • Department of Quality, StemMedical A/S, Soeborg, Denmark.

Zitieren

APA

Minculescu, L., Reekie, J., Petersen, S. L., Kornblit, B. T., Schjoedt, I., Andersen, N. S., Andersen, L. P., Fischer-Nielsen, A., Haastrup, E. K., Friis, L. S., & Sengelov, H. (2024). Donor Lymphocyte Infusion Is a Feasible Way to Improve Survival in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Who Relapse after Allogeneic Stem Cell Transplantation. Acta Haematologica, 147(3), 325-332. https://doi.org/10.1159/000534315

Vancouver

Minculescu L, Reekie J, Petersen SL, Kornblit BT, Schjoedt I, Andersen NS, et al. Donor Lymphocyte Infusion Is a Feasible Way to Improve Survival in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Who Relapse after Allogeneic Stem Cell Transplantation. Acta Haematologica. 2024;147(3):325-332. doi:10.1159/000534315

BibTeX
@article{Minculescu2024,
  author = {Minculescu, Lia and Reekie, Joanne and Petersen, Soeren Lykke and Kornblit, Brian Thomas and Schjoedt, Ida and Andersen, Niels Smedegaard and Andersen, Lisbeth Pernille and Fischer-Nielsen, Anne and Haastrup, Eva Kannik and Friis, Lone Smidstrup and Sengelov, Henrik},
  title = {Donor Lymphocyte Infusion Is a Feasible Way to Improve Survival in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Who Relapse after Allogeneic Stem Cell Transplantation},
  journal = {Acta Haematologica},
  year = {2024},
  volume = {147},
  number = {3},
  pages = {325--332},
  doi = {10.1159/000534315}
}
Kostenlos starten →